Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

December 18, 2019

Study Completion Date

September 11, 2026

Conditions
Invasive Breast CarcinomaStage II Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Triple-Negative Breast Carcinoma
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Carboplatin

Given IV

PROCEDURE

Lumpectomy

Undergo lumpectomy

PROCEDURE

Mastectomy

Undergo mastectomy

DRUG

Paclitaxel

Given IV

Trial Locations (14)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

43210

Ohio State University Comprehensive Cancer Center, Columbus

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH